Platelets Recruit Human Dendritic Cells Via Mac-1/JAM-C
Interaction and Modulate Dendritic Cell Function In Vitro
Harald F. Langer, Karin Daub, Gregor Braun, Tanja Schönberger, Andreas E. May, Martin Schaller,
Gerburg M. Stein, Konstantinos Stellos, Andreas Bueltmann, Dorothea Siegel-Axel, Hans P. Wendel,
Hermann Aebert, Martin Roecken, Peter Seizer, Sentot Santoso, Sebastian Wesselborg,
Peter Brossart, Meinrad Gawaz
Objective—Thrombotic events and immunoinflammatory processes take place next to each other during vascular
remodeling in atherosclerotic lesions. In this study we investigated the interaction of platelets with dendritic cells
(DCs).
Methods and Results—The rolling of DCs on platelets was mediated by PSGL-1. Firm adhesion of DCs was mediated
through integrin ␣M2 (Mac-1). In vivo, adhesion of DCs to injured carotid arteries in mice was mediated by
platelets. Pretreatment with soluble GPVI, which inhibits platelet adhesion to collagen, substantially reduced
recruitment of DCs to the injured vessel wall. In addition, preincubation of DCs with sJAM-C significantly reduced
their adhesion to platelets. Coincubation of DCs with platelets induced maturation of DCs, as shown by enhanced
expression of CD83. In the presence of platelets, DC-induced lymphocyte proliferation was significantly enhanced.
Moreover, coincubation of DCs with platelets resulted in platelet phagocytosis by DCs, as verified by different cell
phagocytosis assays. Finally, platelet/DC interaction resulted in apoptosis of DCs mediated by a JAM-C–
dependent mechanism.
Conclusions—Recruitment of DCs by platelets, which is mediated via CD11b/CD18 (Mac-1) and platelet JAM-C, leads
to DC activation and platelet phagocytosis. This process may be of importance for progression of atherosclerotic lesions.
(Arterioscler Thromb Vasc Biol. 2007;27:1463-1470.)
Key Words: adhesion molecules 䡲 cell trafficking 䡲 dendritic cells 䡲 platelets
B
eyond their role in hemostasis and thrombosis,1 platelets represent an important linkage between thrombosis, inflammation, and atherogenesis.2 Moreover, there is
growing evidence regarding the importance of dendritic
cells (DCs) in the pathogenesis of atherosclerosis and of
vulnerable coronary plaques.3 In atherosclerotic plaques,
the number of DCs is substantially enhanced and DCs
preferentially accumulate at rupture-prone regions.4,5 Recently, DCs were shown to accumulate in the intima of
atherosclerosis-predisposed regions of the aorta of
C57BL/6 mice.6
However, the mechanisms involved in the recruitment of
circulating DCs at site of vascular lesions are poorly understood so far.
It is well recognized that platelets rapidly adhere to the
extracellular matrix of the subendothelium at sites of vascular
lesions. If this process is controlled, platelets passivate
vascular injury and initiate the healing process.1 However,
uncontrolled platelet-mediated thrombus formation leads to
acute thrombotic occlusion or plaque progression resulting in,
eg, acute coronary syndrome.7
Platelet-mediated cell recruitment to the atherosclerotic
plaque plays a central role for vascular repair mechanisms.
DCs participate both in the innate and adaptive immune
system and represent highly specialized antigen-presenting
cells.8 Thereby, they are capable of stimulating naive,
memory, and effector T-cells, as well as activating natural
killer cells.8 Proteins are internalized by phagocytosis,
degraded into short peptides, and presented via the MHC II
receptors.9 During maturation, DCs express various adhesion receptors, which enable DCs to interact with other cell
types and mediate homing of DCs to target tissues.4,8
Original received September 24, 2006; final version accepted February 21, 2007.
From Innere Medizin (H.F.L., K.D., G.B., T.S., A.E.M., K.S., A.B., D.S.-A., P.S., M.G.), Abteilung III, Eberhard Karls University Tuebingen,
Germany; Department of Dermatology (M.S., M.R.), Eberhard Karls University Tuebingen, Germany; Internal Medicine I (G.M.S., S.W.), Eberhard Karls
University Tuebingen, Germany; Department of Thoracic, Cardiac, and Vascular Surgery (H.P.W., H.A.), Eberhard Karls University Tuebingen,
Germany; Institute for Clinical Immunology and Transfusion Medicine (S.S.), Justus-Liebig-University Giessen; Internal Medicine II (P.B.), Eberhard
Karls University Tuebingen, Germany.
P.B. and M.G. contributed equally to this work and both should be considered first authors.
Correspondence to Harald F. Langer, MD, Medizinische Klinik III, Eberhard Karls Universität Tübingen, Otfried-Müller Str. 10, 72076 Tübingen,
Germany. E-mail harald.langer@med.uni-tuebingen.de; or to Meinrad Gawaz, MD, Medizinische Klinik III, Universitätsklinikum Tübingen, OtfriedMüllerstr.10, 72076 Tübingen, Germany. E-mail meinrad.gawaz@med.uni-tuebingen.de
© 2007 American Heart Association, Inc.
Arterioscler Thromb Vasc Biol. is available at http://www.atvbaha.org
DOI: 10.1161/ATVBAHA.107.141515
1463
Downloaded from http://atvb.ahajournals.org/
by guest on February 13, 2016
1464
Arterioscler Thromb Vasc Biol.
June 2007
The present study evaluates the role of platelets for DC
adhesion to vascular lesions and shows that platelets play a
critical role for the recruitment and function of DCs.
Materials and Methods
DCs were generated from buffy coats derived from healthy donors and
differentiated to immature monocyte-derived DCs or mature DCs
(MDCs) (supplemental Figure I, please see http://atvb.ahajournals.
org). For blocking experiments, soluble Fc fusion proteins JAM-AFc, JAM-C-Fc, GPVI-Fc, and Fc-control were generated. Adhesion
of DCs to platelets (all experiments were performed with isolated
platelets) was evaluated in vitro using a static adhesion assay, as well
as a dynamic flow model simulating arterial shear rates with and
without blocking fusion proteins or antibodies. Recruitment of DCs
by platelets in vivo was evaluated by intravital microscopy in mice.
Transmission electron microscopy was used to analyze platelet phagocytosis by DCs and direct interaction between the 2 cells. Phenotyping
of DCs and differentiation of DCs by platelets was evaluated by flow
cytometry, activation of DCs by platelets using a mixed lymphocyte
reaction assay with and without blocking substances. Platelet phagocytosis by DCs further was visualized by phase contrast microscopy,
standard and confocal immunofluorescence microscopy and flow cytometry. Platelet-induced DC apoptosis was measured by propidium
iodide staining, the method of Nicoletti et al, and terminal deoxynucleotidyl transferase-catalyzed deoxyuridinephosphate-nick end labeling
(terminal deoxynucleotidyl transferase-mediated deoxyuridinephosphate nick end-labeling assay).
For detailed Material and Methods, please see
http://atvb.ahajournals.org
Results
Dendritic Cells Adhere to Immobilized Platelets
Under Static and Dynamic Flow Conditions
Platelets play a critical role in the recruitment and adhesion of
circulating blood leukocytes toward vascular lesions.2 Recently, we could demonstrate that immobilized platelets are
able to interact with and to recruit endothelial progenitor
cells.10 Besides endothelial progenitor cells, dendritic cells
have been postulated to play a role in vascular repair
mechanisms and atherosclerosis.3,4 To test whether DCs bind
to platelets, isolated platelets (2⫻108/mL) were allowed to
adhere to 96-well plates coated with collagen type I. Subsequently, immature DCs (immature monocyte-derived DCs) or
MDCs were added to the wells and adhesion of DCs on
platelets was evaluated. Under static conditions, DCs substantially adhered to immobilized platelets compared with
immobilized collagen type I alone (n⫽6; P⬍0.05; Figure 1A,
1B). Adhesion of DCs to platelets was dependent on the
maturation status, as adhesion of MDC onto platelets was
significantly enhanced compared with immature monocytederived DCs (n⫽6; P⬍0.05; Figure 1B). In the control
experiment, adhesion of DCs to immobilized fibronectin was
run in parallel.11 To further characterize adhesion of DCs to
platelets, DCs were coincubated with adherent platelets and
evaluated by electron microscopy. We found that platelets
attached to DCs via forming pseudopodia, indicating that
specific adhesion receptors are involved (Figure 1C). To
evaluate, whether DC adhesion to immobilized platelets
occurs in vivo, we used a carotid injury model of intravital
microscopy as described.12 We found that virtually no adhesion of DCs to the intact carotid vessel wall occurs (Figure
1D). However, after vascular injury adhesion of circulating
DCs to the site of injury occurs rapidly (Figure 1D). Both
Figure 1. Interaction of DCs with platelets under static conditions.
A, 96-well plates precoated with collagen I (10 g/mL) were incubated with or without freshly isolated platelets in order to achieve
adherent platelet layers as described in Materials and Methods.
DCs (1⫻105/mL) were allowed to adhere to these plates. After 30
minutes, the plates were gently washed twice and adherent DCs
were quantified by using a defined frame that was projected to
each photograph. Wells coated with fibronectin (10 g/mL) served
as positive control. B, The mean and SD of 6 independent experiments are shown. *P⬍0.05 as compared with control. C, DCs
(1⫻105/mL) were incubated with freshly isolated platelets (2⫻108/
mL) and transmission electron microscopy was performed as
described in Materials and Methods to visualize interaction of DCs
with platelets (Plt) (magnification ⫻12.000); Ps indicates pseudopodium. D, To assess DC recruitment by platelets in vivo, we used
intravital fluorescence microscopy. Virtually no DCs adhered to the
intact vessel wall of mouse carotid arteries; 5 minutes after induction of vascular injury by ligation, the number of transient as well as
firmly adherent DCs increased significantly. The mean and SD of 6
independent experiments are shown. *P⬍0.001 as compared with
noninjured vessels.
Downloaded from http://atvb.ahajournals.org/ by guest on February 13, 2016
Langer et al
transient and firm adhesion was evident and reached a
maximum at 5 minutes and finally reached plateau (Figure
1D). To further analyze the role of platelets for DC recruitment to vascular lesions, mice were pretreated with the
soluble collagen receptor GPVI-Fc, which inhibits adhesion
of platelets to the injured carotid artery in vivo.13 Pretreatment of mice with soluble collagen receptor GPVI-Fc significantly reduced adhesion of DCs 5 minutes (P⬍0.005) and 30
minutes (P⬍0.05) after induction of injury (supplemental
Figure II). Thus, adhesion of DCs to platelets occurs in vivo.
Next, we analyzed adhesion receptors expressed on DCs
that are potentially involved in adhesion to immobilized
platelets. We found that both subunits of the 2-integrin
Mac-1, CD11b (␣M-subunit), and CD18 (2-subunit), are
highly expressed on DCs (supplemental Figure III). Moreover, CD29 (1-subunit), CD49d (␣4-subunit), and CD162
(PSGL-1) were substantially surface expressed on DCs.
Interestingly, surface expression of the 2-chain was further
enhanced in DCs cultivated in the presence of MDC compared with immature monocyte-derived DCs (supplemental
Figure III).
Next, we evaluated the determinants that mediate DC
adhesion to platelets under arterial flow conditions. In a
parallel plate flow chamber, DCs cultured in the presence of
granulocyte-macrophage colony-stimulating factor/IL-4/
CD40L (MDC) were perfused over platelets immobilized on
collagen type I at a wall shear rate of 2000 s⫺1 as described.10
Cell rolling was significantly enhanced on platelets compared
with the collagen surface alone (Figure 2A). Preincubation
with a blocking monoclonal antibody to CD162, but not with
a control antibody (2D1), significantly reduced this cell
rolling (Figure 2A). Furthermore, DCs showed enhanced firm
adhesion to immobilized platelets compared with immobilized collagen alone (Figure 2B, 2C). When DCs were
preincubated with a blocking anti-CD18 mAb (5 g/mL),
firm adhesion of DCs to immobilized platelets was significantly reduced compared with experiments in which an
irrelevant mAb (2D1) was used (Figure 2B, 2C). This
indicates that the 2-integrin is critically involved in DC/
platelet adhesion. In contrast, a blocking mAb directed
against CD49d had no effect on DC adhesion onto platelets
(Figure 2B, 2C). To identify the platelet counter receptor/
ligand for DCs, we evaluated the effect of soluble recombinant JAM-C fusion protein (sJAM-C), which is known as the
heterophilic counter-receptor of Mac-1 integrin, on DC/platelet adhesion. For the control experiments, sJAM-A, soluble
collagen receptor GPVI-Fc, sGPIb, or Fc was applied. In the
presence of sJAM-C, but not sJAM-A, sGPIb, soluble collagen receptor GPVI-Fc (not shown), or Fc, DC–platelet
interaction was significantly (P⬍0.05, n⫽4 to 8) reduced
(Figure 2D, 2E). To identify the distinct 2-integrin involved
in the adhesion process, further experiments with blocking
monoclonal antibodies were performed. Although there was a
certain reduction in adhesion after pre-incubation with an
anti-CD11c mAb, an obvious decrease in DC adhesion to
platelets could be observed after pre-incubation with an
anti-CD11b mAb, which showed statistical significance
(P⫽0.006) only in this group (Figure 2F). Taken together,
these data indicate that PSGL-1 mediates an initial contact
Platelets and Dendritic Cells
1465
between DCs and platelets under arterial flow conditions
followed by firm adhesion mediated to a substantial part via
Mac-1/JAM-C.
Platelets Induce Differentiation of DCs and
Enhance Their Capacity to Stimulate
Lymphocyte Proliferation
Coincubation of DCs with platelets over several days suggested an induced differentiation of the DCs as evidenced by
enhanced expression of CD83 (Figure 3A), which reached a
plateau at day 3 as evaluated by coexpression of CD1a/CD83
(Figure 3B). Furthermore, expression of differentiation markers CD1a/CD83, CD54, CD40, and CCR-7 was evaluated in
the presence of blocking mAbs to CD40L, CD18, PF-4, or
sJAM-C (Figure 3C). Pre-incubation with a blocking mAb to
CD18 or sJAM-C reduced coexpression of CD1a/CD83 and
expression of CCR-7, but not expression of CD54 and CD40
in the presence of platelets. Pre-incubation with a blocking
mAb to platelet factor 4 (anti-PF-4) reduced coexpression of
CD1a/CD83, expression of CD54, CD40, and CCR-7 in the
presence of platelets; mAb to CD40L, however, had no effect
on the expression of these differentiation markers under
platelet influence (Figure 3C).
The ability of the generated DC populations to stimulate
allogenic T-cell responses was furthermore analyzed in a
mixed lymphocyte reaction.14 DCs coincubated with platelets
showed an enhanced T-cell stimulatory capacity, dependent
on the maturation stimulus used (Figure 3D). Immature DCs
cultivated in the presence of granulocyte-macrophage colonystimulating factor/IL-4 showed clearly increased T-cell stimulation after exposure to platelets (n⫽3, P⬍0.05; Figure 3D),
similar to DCs additionally treated with CD40L but without
platelets. However, DCs cultivated in the presence of
granulocyte-macrophage colony-stimulating factor/IL-4/
CD40L (MDC) revealed a further enhanced T-cell stimulatory capacity, when additionally coincubated with platelets
(n⫽3, P⬍0.05; Figure 3D). Thus, platelets substantially
enhance the capacity of DCs to initiate lymphocyte proliferation, a critical step in the initiation of primary immune
responses. To further characterize the influence of platelets
on DC activation, we performed additional mixed lymphocyte reaction assays with or without blocking monoclonal
antibodies. We found that a blocking mAb to CD40L significantly (n⫽4, P⬍0.05) reduced lymphocyte proliferation
induced by DCs that were exposed to platelets (Figure 3E). A
blocking mAb to CD18 or sJAM-C, however, had no effect in
this setting (Figure 3E).
Phagocytosis of Platelets by DCs After
Prolonged Interaction
To further characterize the interaction of DCs with platelets,
we coincubated these 2 cell types for up to 12 days. After 3
to 7 days, platelets started to disappear and after ⬇10 days of
coincubation; virtually none of the platelets could be found
extracellularly (Figures 4A and 5A). In turn, DCs showed
brown intracellular granules, probably representing phagocytosed platelets (Figure 4A). To further analyze phagocytosis
of platelets by DCs, platelets were labeled with the Fluorochrome Celltracker orange CMTMR and added to DCs. After
Downloaded from http://atvb.ahajournals.org/ by guest on February 13, 2016
1466
Arterioscler Thromb Vasc Biol.
June 2007
Figure 2. Adhesion of DCs to immobilized platelets under arterial shear conditions. (A,B,C) Coverslips were precoated with collagen I
(10 g/mL) and additionally pre-incubated with or without freshly isolated platelets (2⫻108/mL) to achieve adherent platelet layers as
described in Materials and Methods. Resuspended DCs (2.5⫻105/mL) were perfused over these coverslips in a flow chamber using arterial shear rates. In similar fashion, DCs were perfused over immobilized platelets in the presence or absence of blocking mAbs (5
g/mL) as indicated. From minutes 2 to 3, 5 to 6, and 8 to 9, rolling DCs were counted (n⫽4, A). *P⬍0.05 as compared with control
antibody. After 10 minutes, firmly adherent DCs were quantified by offline counting (n⫽4; B,C). The mean and SD of 4 independent
experiments are shown. *P⬍0.05 as compared with control-IgG. C, Representative offline images of perfusion experiments after 10
minutes. D, To identify the involved counterreceptor for DC adhesion on platelets, isolated platelets were immobilized on collagen and
incubated with DCs with or without soluble Fc fusion proteins as described in Materials and Methods. *P⬍0.05 as compared with control, n⫽4 to 8. E, Representative microscopy images of these experiments. F, To further characterize the receptor mediating adhesion
to platelets on DCs, isolated platelets were immobilized on collagen and incubated with DCs with or without blocking monoclonal antibodies. *P⬍0.05 as compared with control, n⫽4.
Downloaded from http://atvb.ahajournals.org/ by guest on February 13, 2016
Langer et al
Platelets and Dendritic Cells
1467
7 days, substantial amounts of fluorescent platelets were
found within DCs as verified by confocal fluorescence
microscopy (Figure 4B). Using transmission electron microscopy, we further visualized the process of platelet phagocytosis (Figure 4C). Platelets initiate the contact with DCs via
protrusions (Figures 4C and 1C). Subsequently, platelets are
incorporated and lysed to cell fragments (Figure 4C). To
analyze the exact kinetics of platelet uptake by DCs, platelets
were labeled with mepacrine and DCs were analyzed by flow
cytometry at different days. Hereby, we could show that
platelet uptake started after 3 days and reached a maximum at
5 to 7 days (Figure 4D). Similarly, time-lapse experiments
showed that platelets are phagocytosed at this time point
(supplemental film, please see http://atvb.ahajournals.org).
Platelets Induce Apoptosis of DCs
Recently, platelets have been described to induce apoptosis of
endothelial cells.15 We analyzed the importance of platelet/DC interaction for the induction of apoptosis of DCs using
propidium iodide staining as described in Materials and
Methods. After coincubation of DCs with isolated platelets,
vesicles appeared around DCs (Figure 5A), indicating apoptosis of DCs. Using the same coincubation model and the
method of Nicoletti et al, induction of apoptosis was significantly enhanced in DCs (immature monocyte-derived DCs
and MDCs) treated with platelets compared with control
(P⬍0.05; Figures 5B, IV). Mitomycin C treatment of DCs,
which served as positive control, showed similar levels of
apoptotic cell death (Figure 5B and supplemental Figure IV).
Similarly, using a terminal deoxynucleotidyl transferasemediated deoxyuridinephosphate nick end-labeling assay, we
could show, that platelets induced apoptosis of DCs (P⬍0.05,
n⫽3; Figure 5C). Analyzing the kinetics of platelet-induced
DC apoptosis by propidium iodide staining, we could show
that apoptosis starts after 3 to 5 days and reaches a maximum
after 7 days (Figure 5D). To further elucidate the mechanisms
mediating platelet-induced DC apoptosis, we performed experiments with pre-incubation with blocking antibodies and
the method of Nicoletti et al Thereby, we could show, that the
presence of sJAM-C or a blocking mAb to CD11b resulted in
significantly decreased apoptosis of DCs (Figure 5E), suggesting this to be one of the central responsible mechanisms.
Figure 3. Effect of platelets on DC differentiation and activation.
A, DCs were coincubated with platelets and analyzed by fluorescence-activated cell sorter flow cytometry. After 24 hours,
DCs coincubated with platelets showed enhanced expression of
CD83 and CD86 and virtually no expression of CD14. B, Coexpression of CD1a/CD83 was enhanced after 1 day and showed
a maximum increase after 2 to 3 days. C, Additionally, expressions of differentiation markers CD1a/CD83, CD54, CD40, and
CCR-7 were evaluated with or without blocking mAbs to
CD40L, CD18, and PF-4 or sJAM-C (n⫽4). D, After coincubation
with platelets, DCs were irradiated and PBMNCs were added.
Proliferation was measured in a mixed lymphocyte reaction
assay. Platelets were able to activate PBMNCs as shown by a
significant increase in proliferation. Proliferation was measured
by 3H-thymidin incorporation (CPM indicates counts per minute).
*P⬍0.05 compared with control. E, Immature monocyte-derived
DCs were exposed to platelets with or without application of
blocking mAbs to CD40L, CD18, or sJAM-C. *P⬍0.05 as compared with control, n⫽4.
Downloaded from http://atvb.ahajournals.org/ by guest on February 13, 2016
1468
Arterioscler Thromb Vasc Biol.
June 2007
Application of a blocking antibody to PDGF-AB showed a
slight, yet not significant decrease, whereas inhibition of
CD40L revealed virtually no reduction of DC apoptosis
(Figure 5E).
Discussion
In this study, we have shown that platelets regulate adhesion
and function of DCs in vitro. The major findings are as
follows. DCs adhere to immobilized platelets via the CD11b/
CD18 complex (␣M2, Mac-1) after an initial contact has been
established by dendritic cell PSGL-1. Blocking experiments
further showed that CD11c and JAM-A play a minor, yet not
significant, role. Platelets enhance the capacity of DCs to
initiate lymphocyte proliferation. DCs phagocyte platelets
and undergo apoptosis, which was mediated by JAM-C. The
recruitment of DCs by platelets to injured carotid arteries in
vivo, as verified by intravital microscopy, emphasizes the
(patho-) physiological relevance of the identified mechanism.
Atherosclerosis is a chronic disease that involves thrombotic
but also immunoinflammatory mechanisms.16
DCs are found in the intima of atherosclerosis-prone vessel
areas and form cell clusters.6,17 During atheroprogression, the
number of DCs markedly increases preferentially within
plaque shoulders, which represent plaque rupture-prone regions4,5 associated with plaque destabilization,18 indicating
that DCs might be involved in the process of atherosclerosis.
DCs can originate from CD34⫹ progenitor cells and DC
precursors, which circulate via the bloodstream to reach their
target tissues.4,9 However, the mechanisms that regulate DC
recruitment toward the atherosclerotic plaque are not
understood.
Platelets accumulate within seconds to sites of vascular
injury and release a variety of potent chemotactic factors and
adhesion receptors onto the platelet surface that induce
recruitment of circulating blood cells toward sites of vascular
lesions.1 Recently, circulating endothelial progenitor cells
have been shown to home at sites of vascular lesions,19 most
likely mediated by adherent platelets.10
In the present study, we show that DCs adhere to immobilized platelets under flow conditions similar to arterial shear
rates. Our data suggest that PSGL-1, which is surfaceexpressed on DCs, is able to mediate an initial contact
between platelets and DCs. We found that both subunits
Figure 4. Coincubation of DCs with platelets. A, Platelets were
coincubated with DCs in 96-well plates up to 12 days. After 3 to
7 days, platelets increasingly disappeared and in projection to
DCs (Š), brown vesicles could be observed. B, To verify platelet
phagocytosis by dendritic cells, platelets (2⫻108/mL) were
labeled with the Fluorochrome Celltracker orange CMTMR and
coincubated with DCs for 7 days in chamber slides. Subsequently, cells were analyzed by standard and confocal fluorescence microscopy. C, Furthermore, transmission electron
microscopy was performed as described in Materials and Methods. Hereby, we could clearly visualize an established contact
(⬍) between DCs (Š) and platelets (3), internalization, and
finally lysis of the platelets resulting in intracellular platelet components within DCs (magnification as indicated in photographs).
D, Platelets were stained with mepacrine and after coincubation
of DCs with these platelets, phagocytosis was analyzed by
assessment of mepacrine-positive DCs using flow cytometry
from days 1 to 11. DCs alone served as control.
Downloaded from http://atvb.ahajournals.org/ by guest on February 13, 2016
Langer et al
Platelets and Dendritic Cells
1469
CD11b/CD18 of the ␣M2 integrin (Mac-1) are highly
surface-expressed on DCs and that adhesion of DCs onto
platelets is mediated by CD11b/CD18 but not CD49d. Previously it was shown that DCs bind to fibronectin, possibly
via 1-integrins.11 Similarly, in our studies immature DCs
bound to fibronectin, but obviously weaker to collagen,
which is the major constituent of the extracellular matrix of
atherosclerotic plaques. However, when platelets adhere to
collagen, they are activated and mediate adhesion of DCs via
interaction with 2-integrin. In the present study we could
show that JAM-C,20 but not GPIb21 or fibrinogen,22 acts as a
specific counter receptor, which is required on platelets to
mediate DC adhesion under arterial shear rates.
Hagihara et al23 demonstrated that activated platelets induce IL-10 –producing MDCs in vitro derived from mononuclear cells. Similar to the study by Hagihara et al, our data
indicate that platelets induce a differentiation of DCs, as
shown by enhanced coexpression of CD1a/CD83, which
started already after 1 day and peaked at days 2 to 3 of
coincubation. Furthermore, we could show that platelets
enhance the capacity of DCs to initiate lymphocyte proliferation. Thus, once adherent to platelets, DCs are stimulated to
regulate immunoinflammatory responses. Activated platelets
release a variety of potent inflammatory compounds, including IL-1, CD40 ligand, or growth factors, that might stimulate
maturation and function of DCs. Thus, it is tempting to
speculate that in the microenvironment of adherent platelets,
immature DCs adhere and mature through stimulation of
platelet-derived compounds.23 Because of our experiments,
CD40L as one of these candidate substances is involved in
platelet-mediated DC activation, as a blocking mAb to
CD40L could reduce the effect of platelets on DCs in a mixed
lymphocyte reaction.
Once homed to target tissues, DCs continuously and
efficiently sample the antigenic content of their microenvironment by phagocytosis.8 We found that platelets are substantially internalized into DCs. As platelets and DCs were
coincubated over several days, the platelets presumably were
activated. When platelets were coincubated for up to 12 days
with DCs, a complete uptake of platelets was obvious.
Because platelet-containing DCs changed their morphology
Figure 5. Platelet induced apoptosis of DCs. A, After coincubation of DCs with platelets, platelets were phagocyted by DCs
and disappeared. Instead, after 7 to 12 days, around DCs vesicles appeared (arrow), indicating an apoptotic process. B and
supplemental Figure IV, DCs were incubated with isolated platelets for 9 days. Mitomycin C-treated (25 g/mL) DCs served as
positive control. Subsequently, induction of apoptosis was
assessed by propidium iodide staining of hypodiploid apoptotic
nuclei and flow cytometry. Compared with untreated cells, DCs
incubated with isolated platelets revealed significantly increased
levels of apoptosis, similar to the positive control. *P⬍0.05 vs
control; n⫽4. C, After incubation with platelets, mitomycin C, or
control, a terminal deoxynucleotidyl transferase-mediated
deoxyuridinephosphate nick end-labeling assay was performed,
as described in Materials and Methods. Compared with control,
significantly more apoptosis could be detected in DCs exposed
to platelets and in the positive control group. P⬍0.05; n⫽3. D,
To evaluate kinetics of platelet-induced apoptosis of DCs, propidium iodide staining of hypodiploid apoptotic nuclei and flow
cytometry was performed from days 1 to 11. Platelet induced
apoptosis of DCs started at day 3 and reached a maximum at
day 7. E, Similarly, on day 7, apoptosis was evaluated with or
without pre-incubation with blocking soluble proteins or blocking monoclonal antibodies as indicated. P⫽0.001 compared
with DCs and platelets; n⫽3.
Downloaded from http://atvb.ahajournals.org/ by guest on February 13, 2016
1470
Arterioscler Thromb Vasc Biol.
June 2007
significantly, we asked whether they undergo apoptosis. We
found that platelet phagocytosis induces apoptosis of DCs as
measured by the generation of hypodiploid apoptotic nuclei
and terminal deoxynucleotidyl transferase-mediated deoxyuridinephosphate nick end-labeling assay. Interestingly,
platelet phagocytosis and DC apoptosis occurred at parallel
time points, possibly implying that the one may be linked to
the other process. By experiments with blocking proteins, we
could show that JAM-C/CD11b is of importance for this
process. Our experimental data are strengthened by recent
clinical data, which indicate that DCs may be involved in
atherosclerosis.3,5,24 For example, application of statins leads
to lower numbers of DCs in atherosclerotic plaques.5 An
interaction between platelets and dendritic cells thus may be
one of the critical cellular links between atherosclerosis and
immunologic processes.
Acknowledgments
We acknowledge the excellent technical assistance of Sarah Gehring,
Iris Schäfer, Alexandra Gau, Heike Runge, Sylvia Stephan, Solveig
Daecke and Birgit Fehrenbacher.
Sources of Funding
The study was supported by grants of the Deutsche Forschungsgemeinschaft (GRK1302 to S.W., SFB 685 to P.B. and S.W., We
1801/2-4 to S.W., and Graduiertenkolleg MA2186/3-1 “Zellbiologische Mechanismen immunassoziierter Prozesse,” GK 794, and Nr.
2186/3-1 to M.G.), the Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (Center for Interdisciplinary
Clinical Research, IZKF; Fö. 01KS9602 to S.W.), SFB 685 (M.R.),
and the Karl und Lore Klein Stiftung and the Sandersstiftung (Nr.
2003.0601 to M.G.), the fortüne program of the UKT, and the
Novartis foundation (H.F.L. and M.G.).
Disclosures
None.
References
1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227–1234.
2. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115:3378 –3384.
3. Bobryshev YV. Dendritic cells in atherosclerosis: current status of the
problem and clinical relevance. Eur Heart J. 2005;26:1700 –1704.
4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease.
N Engl J Med. 2005;352:1685–1695.
5. Yilmaz A, Lochno M, Traeg F, Cicha I, Reiss C, Stumpf C, Raaz D,
Anger T, Amann K, Probst T, Ludwig J, Daniel WG, Garlichs CD.
Emergence of dendritic cells in rupture-prone regions of vulnerable
carotid plaques. Atherosclerosis. 2004;176:101–110.
6. Jongstra-Bilen J, Haidari M, Zhu SN, Chen M, Guha D, Cybulsky MI.
Low-grade chronic inflammation in regions of the normal mouse arterial
intima predisposed to atherosclerosis. J Exp Med. 2006;203:2073–2083.
7. Massberg S, Schulz C, Gawaz M. Role of platelets in the pathophysiology
of acute coronary syndrome. Semin Vasc Med. 2003;3:147–162.
8. Banchereau J, Steinman RM. Dendritic cells and the control of immunity.
Nature. 1998;392:245–252.
9. Lipscomb MF, Masten BJ. Dendritic cells: immune regulators in health
and disease. Physiol Rev. 2002;82:97–130.
10. Langer H, May AE, Daub K, Heinzmann U, Lang P, Schumm M,
Vestweber D, Massberg S, Schonberger T, Pfisterer I, Hatzopoulos AK,
Gawaz M. Adherent platelets recruit and induce differentiation of murine
embryonic endothelial progenitor cells to mature endothelial cells in vitro.
Circ Res. 2006;98:e2–10.
11. Saint-Vis B, Bouchet C, Gautier G, Valladeau J, Caux C, Garrone P.
Human dendritic cells express neuronal Eph receptor tyrosine kinases:
role of EphA2 in regulating adhesion to fibronectin. Blood. 2003;102:
4431– 4440.
12. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier
W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M. A critical
role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002;196:887– 896.
13. Massberg S, Konrad I, Bultmann A, Schulz C, Munch G, Peluso M,
Lorenz M, Schneider S, Besta F, Muller I, Hu B, Langer H, Kremmer E,
Rudelius M, Heinzmann U, Ungerer M, Gawaz M. Soluble glycoprotein
VI dimer inhibits platelet adhesion and aggregation to the injured vessel
wall in vivo. FASEB J. 2004;18:397–399.
14. Appel S, Mirakaj V, Bringmann A, Weck MM, Grunebach F, Brossart P.
PPAR-gamma agonists inhibit toll-like receptor-mediated activation of
dendritic cells via the MAP kinase and NF-kappaB pathways. Blood.
2005;106:3888 –3894.
15. Wassmer SC, de Souza JB, Frere C, Candal FJ, Juhan-Vague I, Grau GE.
TGF-{beta}1 released from activated platelets can induce TNFstimulated human brain endothelium apoptosis: a new mechanism for
microvascular lesion during cerebral malaria. J Immunol. 2006;176:
1180 –1184.
16. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;
340:115–126.
17. Lord RS, Bobryshev YV. Clustering of dendritic cells in athero-prone
areas of the aorta. Atherosclerosis. 1999;146:197–198.
18. Bobryshev YV, Lord RS. Co-accumulation of dendritic cells and natural
killer T cells within rupture-prone regions in human atherosclerotic
plaques. J Histochem Cytochem. 2005;53:781–785.
19. Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler S.
Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation. 2003;108:2511–2516.
20. Santoso S, Sachs UJ, Kroll H, Linder M, Ruf A, Preissner KT, Chavakis T.
The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med. 2002;196:679 – 691.
21. Chavakis T, Santoso S, Clemetson KJ, Sachs UJ, Isordia-Salas I, Pixley
RA, Nawroth PP, Colman RW, Preissner KT. High molecular weight
kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and
glycoprotein Ib. J Biol Chem. 2003;278:45375– 45381.
22. Konstantopoulos K, Neelamegham S, Burns AR, Hentzen E, Kansas GS,
Snapp KR, Berg EL, Hellums JD, Smith CW, McIntire LV, Simon SI.
Venous levels of shear support neutrophil-platelet adhesion and neutrophil aggregation in blood via P-selectin and beta2-integrin. Circulation. 1998;98:873– 882.
23. Hagihara M, Higuchi A, Tamura N, Ueda Y, Hirabayashi K, Ikeda Y,
Kato S, Sakamoto S, Hotta T, Handa S, Goto S. Platelets, after exposure
to a high shear stress, induce IL-10-producing, mature dendritic cells in
vitro. J Immunol. 2004;172:5297–5303.
24. Ranjit S, Dazhu L, Qiutang Z, Yibo F, Yushu L, Xiang W, Shen CL,
Yuan T. Differentiation of dendritic cells in monocyte cultures isolated
from patients with unstable angina. Int J Cardiol. 2004;97:551–555.
Downloaded from http://atvb.ahajournals.org/ by guest on February 13, 2016
Platelets Recruit Human Dendritic Cells Via Mac-1/JAM-C Interaction and Modulate
Dendritic Cell Function In Vitro
Harald F. Langer, Karin Daub, Gregor Braun, Tanja Schönberger, Andreas E. May, Martin
Schaller, Gerburg M. Stein, Konstantinos Stellos, Andreas Bueltmann, Dorothea Siegel-Axel,
Hans P. Wendel, Hermann Aebert, Martin Roecken, Peter Seizer, Sentot Santoso, Sebastian
Wesselborg, Peter Brossart and Meinrad Gawaz
Arterioscler Thromb Vasc Biol. 2007;27:1463-1470; originally published online March 22,
2007;
doi: 10.1161/ATVBAHA.107.141515
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272
Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636
The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://atvb.ahajournals.org/content/27/6/1463
Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the
Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for
which permission is being requested is located, click Request Permissions in the middle column of the Web
page under Services. Further information about this process is available in the Permissions and Rights
Question and Answer document.
Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints
Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online
at:
http://atvb.ahajournals.org//subscriptions/
Downloaded from http://atvb.ahajournals.org/ by guest on February 13, 2016
Data Supplement (unedited) at:
http://atvb.ahajournals.org/content/suppl/2007/03/26/ATVBAHA.107.141515.DC1.html
Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the
Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for
which permission is being requested is located, click Request Permissions in the middle column of the Web
page under Services. Further information about this process is available in the Permissions and Rights
Question and Answer document.
Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints
Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online
at:
http://atvb.ahajournals.org//subscriptions/
Downloaded from http://atvb.ahajournals.org/ by guest on February 13, 2016
Material and Methods
Reagents
For cultivation of DCs from human mononuclear cells, human granulocyte
macrophage colony stimulating factor (GM-CSF; Leukine Liquid Sargramostin; Berlex
Laboratories, Richmond, CA), interleukin-4 (IL-4; R&D Systems, Wiesbaden,
Germany) and CD40 ligand (CD40L, Biozol, Eching, Germany) were used. Human
fibronectin and collagen I were from Becton Dickinson (BD, Heidelberg, Germany).
Blocking monoclonal antibody (mAb) directed against CD49d (α4-integrin, clone
9F10) was purchased from Immunotech (Marseille, France), CD18 (β2-integrin,clone
IB4) and CD162 (P-Selectin Glycoprotein Ligand-1 (PSGL-1), clone 3E2.25.5 PL-1)
from Ancell (Bayport, USA), CD11a (clone HI111), CD11b (αM integrin, clone
ICRF44), CD11c (clone 3.9) and CD40L from Biozol, Eching, Germany. Blocking
polyclonal Ab to CD11d (clone A01) was from Abnova, Taipei, Taiwan. The mAb AP1
against GPIb was a kind gift from Dr. P. Newman, Blood Research Institute,
Milwaukee, USA. A monoclonal antibody to PDGF-AB was from Promega (Madison,
USA). For flow cytometry, fluorescein isothiocyanate (FITC) or phycoerythrin (PE)
labeled antibodies specific for CD29 (clone 3S3), CD49b (clone AK7), CD49e (clone
SAM-1) and CD49f (clone MCA699) from Serotec (Düsseldorf, Germany), CD49d
(clone 9F10), CD162 (clone KPL-1) and CD18 (clone IB4) from BD, CD41 (clone P2),
CD51 (clone AMF7), CD61 (clone SZ21) and CD11b (clone Bear 1) from
Immunotech, CD62P (clone G1-4) from Ancell and corresponding IgG controls were
used. The fluorochrome celltrackertm orange CMTMR (Molecular Probes, Leiden,
Netherlandes) and quinacrine dihydrochloride (mepacrine, Sigma, Taufkirchen,
Germany) was used to evaluate platelet phagocytosis. Mitomycin C was from Medac
(Hamburg, Germany). Glycocalicin, the soluble extracellular region of GPIbα
(sGPIbα)
1
was a kind gift from Dr. K. Clemetson, Theodor Kocher Institute, Bern,
Switzerland.
Isolation of platelets
Human platelets were isolated as described before.2 Briefly, venous blood was drawn
from the antecubital vein of healthy volunteers and collected in acid citrate dextrose
(ACD)-buffer. After centrifugation at 430 x g for 20 min, platelet-rich plasma (PRP)
was removed, added to Tyrodes-HEPES (HEPES 2.5 mmol/L, NaCl 150 mmol/L, KCl
2.5 mmol/L, NaHCO3 0.36 mmol/L, glucose 5.5 mmol/L, BSA 1 mg/ml, pH 6.5) and
centrifugated at 900 x g for 10 min. After removal of the supernatant, the resulting
platelet pellet was resuspended in Tyrodes-HEPES buffer (pH 7.4 supplemented with
CaCl2, 1 mmol/L; MgCl2, 1 mmol/L).
Isolation of DCs
DCs were generated from buffy coats derived from healthy donors.3,4 In brief,
peripheral blood mononuclear cells (PBMNCs) were isolated by Ficoll/Paque
(Biochrom, Berlin, Germany) density gradient centrifugation of HLA-A02 – positive
buffy coat preparations. Cells were resuspended in serum-free X-VIVO 20 medium
(Cambrex, Verviers, Belgium) and allowed to adhere (1 x 107 cells/ well) in 6-well
plates in a final volume of 2 ml. After 2 hours of incubation at 37°C and 5% CO2,
nonadherent cells were removed. Immature monocyte derived dendritic cells (iMDC)
were generated by culturing the adherent blood monocytes in medium (RPMI 1640
with GlutaMAX-1 supplemented with 10% heat-inactivated fetal calf serum and 100
IU/ml penicillin/streptomycin [Invitrogen, Karlsruhe, Germany]) in the presence of
human recombinant granulocyte macrophage colony - stimulating factor (GM-CSF;
100 ng/ml) and interleukin-4 (IL-4; 20 ng/ml) for 7 days.
5-7
For maturation, iMDC
were additionally treated with CD40L (100 ng/ml) for further 24 hours (-> MDC). After
generation of dendritic cells, prior to each functional experiments, a washing step
was included to remove differentiating substances and DCs were processed with
RPMI medium and cells/ substances as described below.To control purity of the cells
and to exclude presence of cells of the monocyte/macrophage lineage, DCs were
characterized by flow cytometry and verified to be positive for CD1a, CD83, CD80,
CD86, CD40, CD54 and for the human leukocyte antigen DR (HLA- DR), while
lacking the expression of CD14, as described previously 8,9 (Suppl. Fig 1).
Generation of soluble Fc-fusion proteins
Cloning of JAM-A-Fc, JAM-C-Fc, GPVI-Fc and Fc-control.
Fc fusion proteins or Fc control were generated as described before.10 For human
JAM-A
a
PCR
was
performed
with
cgcgggagatctaccaccatggggacaaaggcgcaag-3’
gcgggggcggccgccattccgctccacagcttcc-3’,
for
the
primers
and
human
JAM-C
5’5’-
with
5’-
gcggggggtaccaccatggcgctgaggcggcc-3’ and 5’-gcgggggcggccgcctccgccaatgttcaggtca
-3’. For amplification, the plasmid pcDNA–FRT (BamHI/EcoRV) was used.
Generation and harvesting of JAM-A-Fc (soluble JAM-A, sJAM-A), JAM-C-Fc
(soluble JAM-A, sJAM-C), GPVI-Fc (soluble GPVI, sGPVI) or Fc was performed as
described before.10
Adhesion of DCs to platelets under static and dynamic conditions
Static adhesion. To evaluate DC/ platelet adhesion under static conditions, isolated
platelets (2x108/ml) were allowed to adhere to 96-well plates coated with collagen
type I (10 µg/ml) for 2 hours followed by blocking with BSA (2%). DCs (iMDC, MDC)
were added and incubated for 30 min. After two gentle washing steps with PBS,
residual adherent DCs were counted by direct phase contrast microscopy. As control,
experiments were performed with immobilized fibronectin (10 µg/ml). Where
indicated, DCs (MDC) or platelets were pre-treated with sJAM-C, sJAM-A, sGPVI,
sGPIbα or Fc alone as negative control (20 µg/ml each) or blocking monoclonal
antibodies to CD 11a, CD11b, CD11c, CD11d, CD42 (GPIb).
Dynamic adhesion. Adhesion experiments under flow conditions were basically
performed as previously described.11 In brief, glass coverslips were coated with
collagen type I (10 µg/ml) and used in a flow chamber (Oligene, Berlin, Germany).
Isolated platelets (2x108/ml) were allowed to adhere to collagen-coated coverslips.
Where indicated, DCs were pre-treated with anti-CD162 mAb (5µg/ml), anti-CD18
mAb (5µg/ml), anti-CD49d mAb (5µg/ml) or with an irrelevant mAb (2D1, 5µg/ml)
10
for 30 min before perfusion was started. Perfusion was performed with DCs (MDC)
resuspended in Tyrodes-HEPES buffer (pH 7.4 CaCl2, 1 mmol/L; MgCl2, 1 mmol/L) at
shear rates of 2000 s-1 (high shear). All experiments were recorded in real time on
video-CD and evaluated off-line.
Carotid ligation in mice and assessment of DC adhesion by intravital
microscopy
To assess DC recruitment by platelets in vivo, we used intravital fluorescence
microscopy as described before.12 Wild-type C57BL6/J mice (Charles River
Laboratories) were anesthesized by intraperitoneal injection of a solution of
midazolame (5 mg/kg body weight; Ratiopharm), medetomidine (0.5 mg/kg body
weight; Pfizer) and fentanyl (0.05 mg/kg body weight, CuraMed/Pharma GmbH).
Polyethylene catheters (Portex) were implanted into the right jugular vein and
fluorescent DCs (5x104 cells/250µl) were injected intraveneously. The right common
carotid artery was dissected free and ligated vigorously near the carotid bifurcation
for 5 min to induce vascular injury.12 Before and after vascular injury, interaction of
the fluorescent DCs with the injured vessel wall was visualized by in situ in vivo video
microscopy of the right common carotid artery using a Zeiss Axiotech microscope
(20x water immersion objective, W 20x/0,5; Carl Zeiss MicroI maging, Inc.) with a
100-W HBO mercury lamp for epi-illumination. Adherent DCs were quantified as
described before.12 Where indicated, mice were pre-treated with soluble GPVI-Fc
(4mg/kg injection 12h and 1h prior to each experiment), which inhibits adhesion of
platelets to the injured carotic artery in vivo
10
or Fc in equimolar concentration as
negative control.
Electron microscopy
For transmission electron microscopy, DCs (MDC) were grown to 70-80% confluency
and coincubated with isolated platelets (2x108/ml) for various time intervals in culture
medium. Subsequently, cells were fixed in Karnovsky`s solution, postfixed in
osmiumtetroxide and embedded in glycid ether prior to electron microscopy.11 For
scanning electron microscopy, DCs were incubated on glass discs. Thereafter, discs
were gently rinsed with isotonic saline to remove weakly attached cells, fixed in 2 %
(w/v) glutaraldehyde in PBS (1 h), dehydrated through ascending grades of ethanol
up to absolute ethanol, mounted, critical point dried, sputtered with gold-palladium,
and analyzed by a scanning electron microscope (Cambridge Stereoscan,
Cambridge, UK).
Flow cytometry
Receptor surface expression of DCs (iMDC/ MDC) was evaluated using flow
cytometry. DCs were incubated with fluorescence-labelled (FITC or PE) mAbs for 30
min as indicated. As control, PE- or FITC- labeled isotype-matched IgG was used. To
evaluate differentiation of DCs (iMDC) under platelet influence, expression of CD1a,
CD14, CD83 and co-expression of CD1a/CD83, CD40, CD54 and CCR-7 on DCs
was analyzed after coincubation of both cells for up to 3 days. To identify
mechanisms involved in platelet mediated DC differentiation, blocking substances
were added as indicated in figure legends. Flow cytometric analysis was performed
on
a
FACScalibur
(Beckton-Dickinson,
Heidelberg,
Germany).
Mean
immunofluorescence (MIF) was used as index of antigen expression.
Mixed-Lymphocyte-Reaction (MLR) assay
To evaluate the activation of DCs by platelets, a mixed lymphocyte reaction (MLR)
assay was carried out.13 Briefly, DCs (iMDC/ MDC, 2.5x105/ml) were coincubated
with or without freshly isolated platelets (2x108/ml) for seven days in 48-well plates at
37°C. Subsequently, cells were detached, washed and adjusted to a concentration of
1x105/ml. To inhibit further proliferation of DCs, the cells were exposed to radiation of
30 Gray. Then, DCs were coincubated with PBMNCs (1x106/ml) in a 96 microtiterwell
for 5 days at 37°C, to evaluate the stimulating effect of the DCs (with or without
platelets) on PBMNC proliferation. This effect was measured by the detection of 3Hthymidin uptake.13 PBMNCs and platelets alone served as an internal control. To
identify mechanisms involved in platelet mediated DC activation, blocking substances
were added as indicated in figure legends.
Coincubation and phagocytosis assays
For coincubation experiments, DCs (2.5x105/ml) were added to isolated platelets
(2x108/ml) for up to 12 days. Visual microscopic controls were carried out daily and
phase contrast images were taken on day 1, 7 and 12.
To visualize phagocytosis of platelets by DCs, platelets were labeled with the
fluorochrome celltrackertm orange CMTMR and coincubated with DCs (iMDC) for 7
days in chamber slides. Subsequently, cells were analyzed by standard and confocal
fluorescence microscopy. To evaluate the kinetics of platelet phagocytosis by DCs,
platelets were stained with mepacrine for 4h and after co-incubation of DCs (iMDC)
with platelets, mean fluorescence intensity was analyzed in the DC gate on day 1, 2,
5, 7 and 11. Moreover using the staining protocol with celltrackertm orange CMTMR,
on day 5 cells (co-cultures) were analyzed by time-lapse fluorescence and phase
contrast microscopy using an Olympus IX 81 microscope (Olympus, Hamburg,
Germany) and cell^P software (Olympus Soft Imaging Solutions, LeinfeldenEchterdingen, Germany). The analyses were performed at 37°C in an incubator
containing an atmosphere of 10% CO2 in air (Incubator S, Pecon, Erbach, Germany).
Phase contrast images and celltrackertm orange CMTMR (red) fluorescence were
acquired at 30 min intervals over 48 hours. Data are presented as an overlaid
sequence of phase contrast and fluorescence images.
Apoptosis assay
For detection of apoptosis, DCs (2.5x105/ml culture medium) were coincubated with
platelets (2x108/ml) in 96-well microtiter plates for 9 days. The leakage of fragmented
DNA from apoptotic nuclei was measured by the method of Nicoletti et al.14 Briefly,
apoptotic nuclei from DCs (iMDC/ MDC) were prepared by lysing cells in a hypotonic
lysis buffer (1% sodium citrate, 0.1% Triton X-100 and 50 µg/mL propidium iodide)
and subsequently analyzed by flow cytometry. To identify mechanisms involved in
platelet mediated DC apoptosis, blocking substances were added as indicated in
figure legends. To evaluate the kinetics of DC (iMDC) apoptosis induced by platelets,
apoptosis was analyzed on day 1, 3, 5, 7, 9 and 11 using this method. Furthermore,
to detect DNA-fragments the terminal deoxynucleotidyl transferase (TdT)-catalyzed
deoxyuridinephosphate (dUTP)-nick end labeling (TUNEL) assay was carried out at
day 9 to measure platelet induced DC (iMDC) apoptosis, using the MEBSTAIN
Apoptosis kit Direct (Coulter-Immunotech, Krefeld, Germany) generally following the
instructions of the manufacturer. Briefly, cells were cultured in 24 well plates for the
indicated times, transferred into FACS tubes and washed twice with PBS/0.2%BSA.
Cells were fixed in 4% paraformaldehyde (in 0.1M NaH2PO4, pH 7.4) for 30 min at
4°C followed by 2 washing steps and permeabilization with 70% ethanol at -20°C for
another 30 min. After washing and incubation with TdT and FITC-dUTP for 1h at
37°C, reaction was blocked with PBS/BSA. Mitomycin C treated cells served as
positive control. After washing, cells were measured by flow cytometry.
Data presentation and statistics
Comparisons between group means were performed using Student t-test or ANOVA
analysis. Data are presented as mean + standard deviation. P<0.05 was considered
as statistically significant.
References
Reference List
1. Santoso S, Sachs UJ, Kroll H, Linder M, Ruf A, Preissner KT, Chavakis T. The
junctional adhesion molecule 3 (JAM-3) on human platelets is a
counterreceptor for the leukocyte integrin Mac-1. J Exp Med. 2002;196:679691.
2. Massberg S, Gawaz M, Gruner S, Schulte V, Konrad I, Zohlnhofer D,
Heinzmann U, Nieswandt B. A crucial role of glycoprotein VI for platelet
recruitment to the injured arterial wall in vivo. J Exp Med. 2003;197:41-49.
3. Brossart P, Grunebach F, Stuhler G, Reichardt VL, Mohle R, Kanz L, Brugger
W. Generation of functional human dendritic cells from adherent peripheral
blood monocytes by CD40 ligation in the absence of granulocyte-macrophage
colony-stimulating factor. Blood. 1998;92:4238-4247.
4. Appel S, Mirakaj V, Bringmann A, Weck MM, Grunebach F, Brossart P. PPARgamma agonists inhibit toll-like receptor-mediated activation of dendritic cells
via the MAP kinase and NF-kappaB pathways. Blood. 2005;106:3888-3894.
5. Dorfel D, Appel S, Grunebach F, Weck MM, Muller MR, Heine A, Brossart P.
Processing and presentation of HLA class I and II epitopes by dendritic cells
after transfection with in vitro-transcribed MUC1 RNA. Blood. 2005;105:31993205.
6. Grunebach F, Muller MR, Brossart P. New developments in dendritic cellbased vaccinations: RNA translated into clinics. Cancer Immunol Immunother.
2005;54:517-525.
7. Muller MR, Tsakou G, Grunebach F, Schmidt SM, Brossart P. Induction of
chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell
responses using RNA-transfected dendritic cells. Blood. 2004;103:1763-1769.
8. Nencioni A, Schwarzenberg K, Brauer KM, Schmidt SM, Ballestrero A,
Grunebach F, Brossart P. Proteasome inhibitor bortezomib modulates TLR4induced dendritic cell activation. Blood. 2006;108:551-558.
9. Brossart P, Zobywalski A, Grunebach F, Behnke L, Stuhler G, Reichardt VL,
Kanz L, Brugger W. Tumor necrosis factor alpha and CD40 ligand antagonize
the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic
cells. Cancer Res. 2000;60:4485-4492.
10. Massberg S, Konrad I, Bultmann A, Schulz C, Munch G, Peluso M, Lorenz M,
Schneider S, Besta F, Muller I, Hu B, Langer H, Kremmer E, Rudelius M,
Heinzmann U, Ungerer M, Gawaz M. Soluble glycoprotein VI dimer inhibits
platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J.
2004;18:397-399.
11. Langer H, May AE, Daub K, Heinzmann U, Lang P, Schumm M, Vestweber D,
Massberg S, Schonberger T, Pfisterer I, Hatzopoulos AK, Gawaz M. Adherent
platelets recruit and induce differentiation of murine embryonic endothelial
progenitor cells to mature endothelial cells in vitro. Circ Res. 2006;98:e2-10.
12. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W,
Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M. A critical role of
platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp
Med. 2002;196:887-896.
13. Nencioni A, Lauber K, Grunebach F, Van Parijs L, Denzlinger C, Wesselborg
S, Brossart P. Cyclopentenone prostaglandins induce lymphocyte apoptosis
by activating the mitochondrial apoptosis pathway independent of external
death receptor signaling. J Immunol. 2003;171:5148-156.
14. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and
simple method for measuring thymocyte apoptosis by propidium iodide
staining and flow cytometry. J Immunol Methods. 1991;139:271-279.
Langer and coworkers
Platelets and Dendritic Cells
Figure I (please see www.ahajournals.org)
Dendritic cells were generated from PBMNCs using IL-4/GM-CSF with or without
CD40L. DC morphology and immunologic properties were characterized by scanning
electron microscopy (upper panel) and flow cytometry (lower panel).
After culture on glass disks for scanning electron microscopy, DCs showed an
adhesive phenotype with numerous cellular processes. Furthermore, DCs are
typically positive for CD1a, HLA-DR, CD80, CD86, CD40 and CD54 and negative for
CD14. In more mature DCs, expression of CD83, CD40 and CD54 is increased,
CD14 stays negative. Negative control depicts isotype matched IgG control.
Figure II (please see www.ahajournals.org)
To assess DC recruitment by platelets in vivo, we used intravital fluorescence
microscopy. Mice were pre-treated with soluble GPVI or Fc control 12 h and 1 h prior
to each experiment. Adhesion of DCS was assessed 5 min or 30 min after induction
of vessel injury or when no injury was induced. The mean and standard deviation of
4-6 independent experiments is shown. * indicates p<0.005, # p<0.05 as compared to
Fc control.
Figure III (please see www.ahajournals.org)
Expression of adhesion receptors on the surface of DCs was evaluated by FACS flow
cytometry with FITC- or PE- labeled mAbs. Corresponding isotype-matched IgG
served
as
control
antibody.
The
analysis
of
4
independent
experiments
(mean+standard deviation of the mean fluorescence) is shown. * indicates p<0.05,
p<0.01 vs. IgG control.
1
#
Langer and coworkers
Platelets and Dendritic Cells
Figure IV (please see www.ahajournals.org)
DCs were incubated with isolated platelets for 9 days or Mitomycin C (25 µg/ml) as
positive control. Induction of apoptosis was assessed by propidium iodide staining of
hypodiploid apoptotic nuclei and flow cytometry. Representative dot plots of the flow
cytometry experiments are shown.
Suppl. film
To evaluate kinetics of platelet phagocytosis by DCs, we stained platelets with cell
trackerTM as described in Materials and Methods. Phagocytosis reached a maximum
between d5 – d7 as evidenced by increased red signal in projection to dendritic cells.
2
Fig. I
x 1000
iMDC (IL-4/GM-CSF)
MDC (IL-4/GM-CSF/CD40L)
35,45
35,46
101,36
CD86
CD1a
10,00
5,98
27,52
22,24
1,76
20,09
2,30
49,38
HLA DR
CD80
38,44
CD14
618,59
CD54
CD86
CD83
CD40
CD14
247,96
CD1a
CD80
CD83
82,30
CD40
174,26
HLA DR
CD54
Fig. II
DC adhesion [cells/mm2]
1500
no injury
5 min
30 min
1000
#
*
500
0
Fc
GPVI
Fc
GPVI
injury
Fig. III
CD29
MDC (IL-4/ GM-CSF/ CD40L)
iMDC (IL-4/ GM-CSF)
*
CD49b
*
CD49d
CD49e
CD49f
#
CD11b
*
CD18
CD41
CD51
CD61
CD62P
CD162
*
control IgG
0
100
200
Mean Immunofluorescence
300
Propidium iodide positive (MIF)
Fig. IV
DCs
DCs + Mito C
DCs + Plts
Plts
Forward Scatter